D
Biomea Fusion, Inc. BMEA
$1.99 -$0.14-6.57%
Recommendation
Sell
Prev Close
$2.30
Volume
1,217,497
Avg Vol (90D)
741,316
Market Cap
$83.35M
Dividend & Yield
--
52-Week Range
$2.27 - $16.29
P/E (TTM)
--
EPS (TTM)
-$4.00
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Biomea Fusion's Strategic Shift: A Year of Transformation
4/2/2025 - TipRanks Financial Blog
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/1/2025 - Globe Newswire
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
4/1/2025 - Zacks Investment Research
Biomea Fusion's (BMEA) "Buy" Rating Reaffirmed at HC Wainwright
4/1/2025 - MarketBeat
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
3/31/2025 - GuruFocus
Biomea Fusion reports Q4 EPS (81c), consensus (93c)
3/31/2025 - The Fly
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
3/31/2025 - Globe Newswire
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
3/31/2025 - Zacks Investment Research
Biomea Fusion (BMEA) to Release Earnings on Monday
3/31/2025 - MarketBeat
Biomea Fusion Appoints Interim CEO Amid Leadership Changes
3/27/2025 - TipRanks Financial Blog
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages
3/27/2025 - MarketBeat
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO
3/26/2025 - Seeking Alpha - Healthcare
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO
3/26/2025 - SeekingAlpha.com: All News
Biomea Fusion Announces Leadership Transition
3/25/2025 - GuruFocus
Biomea Fusion names Mick Hitchcock to succeed Thomas Butler as interim CEO
3/25/2025 - The Fly
Biomea Fusion Announces Leadership Transition
3/25/2025 - Globe Newswire
HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA)
3/25/2025 - MarketBeat
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
3/25/2025 - TipRanks Financial Blog
Barclays Sticks to Its Hold Rating for Biomea Fusion (BMEA)
3/25/2025 - TipRanks Financial Blog
Biomea Fusion (BMEA) Gets a Buy from H.C. Wainwright
3/24/2025 - TipRanks Financial Blog
Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)
3/24/2025 - TipRanks Financial Blog
Biomea Fusion price target lowered by $40 at Oppenheimer, here's why
3/24/2025 - The Fly
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
3/24/2025 - TipRanks Financial Blog
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
3/24/2025 - The Fly
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
3/24/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$149.63M
EBIT (TTM)
-$151.32M
Net Income (TTM)
-$144.01M
Balance Sheet
Total Assets (Q)
$110.42M
Total Debt (Q)
$9.57M
Total Liabilities (Q)
$34.45M
Book Value Per Share (Q)
$2.10
Cash Flow
Cash from Operations (TTM)
-$112.73M
Cash from Investing (TTM)
-$288.00K
Cash from Financing (TTM)
$1.88M
Net Change in Cash (TTM)
-$111.14M
Filings
Filing Date
Tuesday, October 29, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
2.14
7-Day Total Return
-28.16%
30-Day Total Return
-46.65%
60-Day Total Return
-48.71%
90-Day Total Return
-69.53%
Year to Date Total Return
-46.07%
1-Year Total Return
-86.99%
2-Year Total Return
-93.85%
3-Year Total Return
-55.38%
5-Year Total Return
--
52-week Low
Mar 27, 2025 - $2.27
52-week High
Apr 01, 2024 - $16.29
Valuation
Market Cap
$83.35M - Micro Cap
Enterprise Value
$4.96M
Price/Sales (TTM)
--
Price/Book (Q)
1.10
Dividends and Shares
Shares Outstanding
36.22M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
biomeafusion.com
Phone Number
650 980 9099
Address
900 Middlefield Road
Redwood City, CA 94063
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings